

February 22, 2024  
Symbio Pharmaceuticals Limited  
Fuminori Yoshida  
Representative Director  
President and Chief Executive Officer  
(Securities Code: 4582)

## Notification of Amendment to the Articles of Incorporation

Symbio Pharmaceuticals Limited (the “Company”) today announced that, pursuant to the resolution passed by the Company’s Board of Directors today, a proposal regarding Amendment of the Articles of Incorporation will be submitted to the 19th Annual General Meeting of Shareholders scheduled to be held on March 22, 2024.

### 1. Purpose of the Amendment to the Articles of Incorporation

For the Company, globalization of our business is an important objective as we approach 2030. Following the establishment of POC (Proof of Concept) of the antiviral efficacy of intravenous brincidofovir (IV BCV) against adenovirus infection in our ongoing Phase II clinical trial in the U.S. of IV BCV in disseminated adenovirus infection in immunocompromised patients who have had hematopoietic stem cell transplantation, we are preparing to start a global Phase III clinical trial, mainly in Europe, the U.S., and Japan. At the same time, we plan to start a Phase II clinical trial in the U.S. for subjects with cytomegalovirus infection who have had hematopoietic stem cell transplantation in the second quarter of this fiscal year.

In addition, we will proceed toward conducting global clinical trials in promising therapeutic areas, such as hematological oncology, solid tumors, and neurodegenerative diseases, in which we are currently conducting pre-clinical studies.

In anticipation of future funding requirements, in addition to internal allocation of funds, the Company is considering exploring business alliances with global pharmaceutical companies and raising funds in the medium to long term.

To enable the Company to implement a flexible and agile capital policy in the future, an amendment will be proposed to increase the total number of authorized shares from the current total of 65 million in advance.

### 2. Proposed amendment

The details of the proposed amendment are as follows:

Current Articles of Incorporation	Proposed Change
Articles 6 (Authorized Shares) The company is authorized to issue <u>65,000,000</u> shares.	Articles 6 (Authorized Shares) The company is authorized to issue <u>115,000,000</u> shares.

### 3. Schedule

Date of Annual General Meeting of Shareholders to amend the Articles of Incorporation: March 22, 2024 (scheduled)

Effective date of the amendment: March 22, 2024 (scheduled)

[Contact] Investor Relations: Tel: +81 (0)3 5472 1125